• 5 min read
• Published on 25 July 2025
Hey! We are Nemo.
Nemo, short for Never Miss Out, is a mobile investment platform that delivers curated, data-driven investment ideas to your fingertips. It offers commission-free trading across stocks, ETFs, crypto, and CFDs, along with AI-powered tools, real-time market alerts, and themed stock collections called Nemes.
Download the App
Scan the QR code to download the Nemo app and start investing on Nemo today
published-on
Read article
published-on
Read article
published-on
Read article
published-on
Read article
published-on
Read article
View the full Basket:Buffett's Billions: The Philanthropy Effect
When Warren Buffett speaks, investors listen. When he buys, they pile in. So, when he gives away billions of dollars, what are we supposed to do? Most people see it as a lovely act of charity, and of course, it is. But I think it’s also one of the most interesting investment signals you could ask for. Following the money is an old adage, but what about following the money that’s being given away with strategic purpose?
Buffett’s recent six billion dollar donation, primarily to the Bill & Melinda Gates Foundation, isn’t just a cheque written to make the world a better place. It’s a colossal injection of capital into a system that operates on a completely different timeline to the rest of us. These foundations don’t just throw money at problems. They act like a state-backed enterprise, creating entire markets from scratch. They fund the research, guarantee the purchase orders, and build the distribution networks. For a company lucky enough to be in their orbit, it’s like having the world’s most patient and deep pocketed client.
View the full Basket:Buffett's Billions: The Philanthropy Effect
It doesn’t take a genius to see that global health is the primary beneficiary here. The Gates Foundation has been on a crusade against diseases like malaria, tuberculosis, and HIV for years. This fresh funding could supercharge their efforts. This is where the big pharmaceutical players come into the picture. Companies like Gilead Sciences, with its long history in HIV treatments, or GlaxoSmithKline, with its vast vaccine portfolio, are not just potential partners, they are essential ones.
These foundations need industrial scale muscle to turn their ambitions into reality. They need companies that can research, manufacture, and distribute on a global scale. Merck is another name that comes to mind, with its own formidable vaccine pipeline. For these firms, a partnership with a major foundation can de-risk projects that might otherwise seem too speculative for the quarterly-minded stock market. It’s a steady, reliable source of funding that is blissfully immune to market panics or interest rate jitters.
View the full Basket:Buffett's Billions: The Philanthropy Effect
Of course, the world’s problems are not confined to the pharmacy. This philanthropic capital flows into other critical areas, too. Take agriculture, for instance. Feeding a growing global population is a monumental challenge, and foundations are pouring money into technologies that improve crop yields and farming efficiency. Companies at the forefront of agricultural science and technology could find themselves with a very powerful backer.
Then there’s education. Closing the digital divide and bringing learning to remote corners of the globe is another key mission. This creates potential opportunities for companies specialising in educational technology, whose platforms can be scaled up with the help of foundation funding. To me, it’s a fascinating way to look at the market, tracking where enormous, patient pools of capital are headed. It’s the kind of thinking that has informed collections of stocks like the Buffett's Billions: The Philanthropy Effect, which groups together companies that may be positioned to benefit from this very trend.
View the full Basket:Buffett's Billions: The Philanthropy Effect
Before you rush off, remember that no investment is a sure thing. This is not a magic bullet. Philanthropic priorities can, and do, shift over time. A project that is a top priority today might be yesterday’s news in five years. Furthermore, foundation backing doesn’t grant immunity from the usual headaches. Regulatory hurdles still exist, and a product still needs to work and be accepted by the market. This is patient capital, not miracle capital. Investing always carries risk, and it’s important to remember that even with the best intentions, things might not pan out as expected.
View the full Basket:Buffett's Billions: The Philanthropy Effect
View the full Basket:Buffett's Billions: The Philanthropy Effect
View the full Basket:Buffett's Billions: The Philanthropy Effect
View the full Basket:Buffett's Billions: The Philanthropy Effect
View the full Basket:Buffett's Billions: The Philanthropy Effect
View the full Basket:Buffett's Billions: The Philanthropy Effect
This article is marketing material and should not be construed as investment advice. No information set out in this article be considered, as advice, recommendation, offer, or a solicitation, to buy or sell any financial product, nor is it financial, investment, or trading advice. Any references to specific financial product or investment strategy are for illustrative / educational purposes only and subject to change without notice. It is the investor’s responsibility to evaluate any prospective investment, assess their own financial situation, and seek independent professional advice. Past performance is not indicative of future results. Please refer to our Risk Disclosure.
published-on
Read article
published-on
Read article
published-on
Read article
published-on
Read article
published-on
Read article